Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Capricor Therapeutics, Inc. - Common Stock
(NQ:
CAPR
)
29.35
-0.33 (-1.11%)
Streaming Delayed Price
Updated: 1:56 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Capricor Therapeutics, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Hewlett Packard Enterprise, Nvidia, Progress Software And Other Big Stocks Moving Higher On Wednesday
↗
September 25, 2024
Via
Benzinga
Nvidia, Alibaba, Capricor Therapeutics, TSMC, Tesla: Why These 5 Stocks Are On Investors' Radars Today
↗
September 24, 2024
On Tuesday, major U.S. indices closed higher, with the Dow Jones Industrial Average gaining 0.2% to reach 42,208.22.
Via
Benzinga
Topics
Stocks
Why Capricor Therapeutics Stock Is Soaring Tuesday
↗
September 24, 2024
Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday after the company announced intent to file a biologics license application (BLA) for the full approval of Deramiocel for the...
Via
Benzinga
Week In Review: Nippon Shinyaku Signs $735 Million Deal For DMD Therapy
↗
September 21, 2024
Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor Therapeutics of San Diego. Nippon Shinyaku will pay $20 million upfront and...
Via
Talk Markets
Deep Dive Into Capricor Therapeutics Stock: Analyst Perspectives (5 Ratings)
↗
September 20, 2024
Via
Benzinga
Unveiling 6 Analyst Insights On Capricor Therapeutics
↗
July 02, 2024
Via
Benzinga
What's Going On With Capricor Therapeutics Stock Friday?
↗
June 28, 2024
The biotechnology company said deramiocel increased cardiac function based on several different measures.
Via
Benzinga
Expert Ratings For Capricor Therapeutics
↗
May 14, 2024
Via
Benzinga
EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm
↗
September 17, 2024
Capricor Therapeutics partners with Nippon Shinyaku for the European commercialization of Duchenne muscular dystrophy treatment, deramiocel, with a potential $1.5 billion in milestone payments from...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
June 11, 2024
Via
Benzinga
What's Going On With Capricor Therapeutics Stock Tuesday?
↗
June 11, 2024
Capricor Therapeutics announced successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA).
Via
Benzinga
What's Going On With Capricor Therapeutics Stock Tuesday?
↗
June 04, 2024
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is trading higher Tuesday after the company announced three-year results from the ongoing HOPE-2 open-label extension
Via
Benzinga
CAPR Stock Earnings: Capricor Therapeutics Misses EPS, Misses Revenue for Q1 2024
↗
May 13, 2024
CAPR stock results show that Capricor Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Recap: Capricor Therapeutics Q4 Earnings
↗
February 29, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
↗
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Capricor Therapeutics's Earnings Outlook
↗
February 28, 2024
Via
Benzinga
Preview: Capricor Therapeutics's Earnings
↗
November 13, 2023
Via
Benzinga
Recap: Capricor Therapeutics Q1 Earnings
↗
May 11, 2023
Via
Benzinga
FlexShopper And 3 Other Penny Stocks Insiders Are Buying
↗
October 12, 2023
The Dow Jones closed higher by around 65 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Cadrenal Therapeutics And 3 Other Stocks Under $3 Insiders Are Buying
↗
October 09, 2023
The Dow Jones closed higher by around 290 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
US Stocks Turn Lower; Dow Tumbles Over 200 Points
↗
September 29, 2023
U.S. stocks turned lower toward the end of trading, with the Dow Jones falling over 200 points on Friday. The Dow traded down 0.70% to 33,432.17 while the NASDAQ fell 0.15% to 13,181.22. The S&P 500...
Via
Benzinga
Topics
Stocks
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
September 29, 2023
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
Via
Benzinga
Earnings Preview For Capricor Therapeutics
↗
March 14, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
September 29, 2023
Via
Benzinga
Crude Oil Down 1% Following PCE Data; Blue Apron Shares Surge
↗
September 29, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Friday. The Dow traded up 0.13% to 33,710.74 while the NASDAQ rose 0.99% to 13,331.54. The S&P 500...
Via
Benzinga
Topics
Stocks
Nasdaq Gains Over 1%; Nike Posts Upbeat Earnings
↗
September 29, 2023
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 1% on Friday. The Dow traded up 0.24% to 33,746.70 while the NASDAQ rose 1.22% to 13,362.51. The S&P 500 also rose,...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
September 29, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
August 29, 2023
Via
Benzinga
Top 5 Health Care Stocks That May Fall Off A Cliff
↗
August 23, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Earnings Scheduled For March 15, 2023
↗
March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
